Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants | Zendy

Andrea Duppenthaler | Zendy; Meri Gorgievski-Hrisoho | Zendy; Christoph Aebi | Zendy

Open Access

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants

Author(s) -

Andrea Duppenthaler,

Meri Gorgievski-Hrisoho,

Christoph Aebi

Publication year - 2001

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2001.09681

Subject(s) - palivizumab , medicine , pediatrics , population , cohort , mechanical ventilation , retrospective cohort study , gestational age , respiratory system , pregnancy , environmental health , biology , genetics

Palivizumab is approved in Switzerland for prevention of hospitalisation for RSV infection in children with one of the following risk factors: (1) history of prematurity < or = 35 weeks and age < or = 6 months or (2) chronic lung disease and age < or = 1 year. Regional data on the expected effectiveness of this monoclonal antibody are not available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research